What does microsatellite instability (MSI) mean for Endometrial Cancer

Understanding Microsatellite Instability (MSI) in Endometrial Cancer

I'm glad you're asking about this—MSI is an important finding that can significantly influence your treatment approach. Let me explain what it means in practical terms.

What MSI Actually Is

Microsatellites are short, repeated sequences of DNA found throughout your genome. Think of them like a typewriter with a spell-checker. Normally, when your cells copy their DNA, any mistakes get caught and fixed by a "mismatch repair" system—like spell-check correcting errors.

With MSI-High (MSI-H), that repair mechanism isn't working properly, so errors accumulate during DNA replication. It's like having a typewriter where the spell-checker is broken—mistakes pile up and don't get corrected.

dMMR (deficient mismatch repair) is essentially the same thing measured a different way—it's looking at whether the repair proteins themselves are missing or broken, rather than looking at the errors that result.

What This Means for Endometrial Cancer

According to the NCCN Guidelines for Endometrial Carcinoma, MSI-H status is one of four major molecular subtypes that doctors use to classify endometrial cancer:

The Four Molecular Subtypes:

1. POLE-mutated — generally good prognosis
2. MSI-H/dMMR — intermediate prognosis, but important for treatment decisions
3. p53 aberrant — most aggressive, requires multimodality treatment
4. NSMP (no specific molecular profile) — intermediate prognosis

Why Your Doctor Tests for MSI

The NCCN Guidelines strongly recommend that all endometrial cancer patients receive molecular testing including:

• POLE mutation testing
• MMR/MSI testing (by immunohistochemistry or molecular assay)
• p53 expression testing

This testing helps your oncology team determine:

• Your prognosis (how the cancer is likely to behave)
• Treatment sensitivity (which therapies are most likely to work)
• Whether you need additional surveillance (some MSI-H cases are linked to Lynch syndrome, a hereditary cancer condition)

Treatment Implications

For MSI-H endometrial cancer specifically:

• Immunotherapy eligibility: MSI-H tumors typically respond well to checkpoint inhibitor immunotherapies (like pembrolizumab/Keytruda), which work by "removing the brakes" on your immune system. When you have MSI-H, your tumor has many mutations that your immune system can recognize as "foreign," making immunotherapy potentially very effective.

• Chemotherapy considerations: The NCCN Guidelines note that MSI-H tumors may respond differently to traditional chemotherapy compared to other molecular subtypes, which may influence whether chemotherapy is recommended.

• Clinical trial opportunities: The NCCN Guidelines specifically encourage clinical trial enrollment for patients with MSI-H endometrial cancer, as there are ongoing studies exploring the best treatment strategies for this molecular subtype.

Important Next Steps

Questions to ask your oncologist:

1. "What is my tumor's molecular classification (POLE, MSI-H, p53 aberrant, or NSMP)?" — This is foundational to your treatment plan.

2. "Does my MSI-H status make me a candidate for immunotherapy?" — This could open up treatment options.

3. "Should I be referred for genetic counseling?" — MSI-H can be associated with Lynch syndrome, which has implications for you and your family members.

4. "Are there clinical trials available for my specific molecular subtype?" — The NCCN Guidelines encourage this exploration.

5. "How does my MSI status influence the chemotherapy recommendation?" — Understanding this helps you make informed decisions about your treatment plan.

The Bottom Line

MSI-H in endometrial cancer is actually informative and actionable—it tells your doctor important things about how your cancer behaves and which treatments are most likely to work. Rather than being a negative finding, it's a roadmap that helps guide personalized treatment decisions.

According to the NCCN Guidelines, the decision to use molecular testing and how to apply it depends on your center's resources and multidisciplinary team, so discussing these results thoroughly with your gynecologic oncologist is essential.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.